Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight-adjusted effective volume of 0.5% ropivacaine for costoclavicular-cervical plexus blocks in arthroscopic shoulder surgery
ChiCTR2400090292Phase 4Not yet recruiting
- Sponsor
- Ningbo No. 6 Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in rotator cuff tear, sponsored by Ningbo No. 6 Hospital. Primary endpoint: Postoperative pain intensity (NRS scores). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
rotator cuff tear
Beyond the preview
Go deeper on ChiCTR2400090292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090292.